Surgery followed by ipilimumab benefited melanoma patients

20 May 2015

A study has demonstrated that a drug called ipilimumab improves the relapse-free survival of advanced stage melanoma patients rendered free of disease surgically but at high risk for relapse. Ipilimumab is approved for the treatment of melanoma that cannot be surgically removed or that has metastasized to different sites.

Ipilimumab restimulates the immune system to target tumor cells

Ipilimumab targets a protein called cytotoxic T lymphocytic antigen-4 (CTLA-4) that is found on a type of immune cell called a T cell. CTLA-4 keeps the immune system in check to avoid autoimmune disease by downregulating T cell activity. Tumors take advantage of CTLA-4 activity to avoid immune detection. By targeting CTLA-4, ipilimumab restimulates the immune system to target tumor cells.

Moffitt Cancer Center researchers participated in an international phase 3 study that demonstrated the positive effect of Ipilimumab.

Patient characteristics associated with a better response to the treatment

The study, which included researchers from 19 countries, compared ipilimumab treatment in 475 people to placebo treatment in 476 people. The analysis of the results showed that:

  • Patients who were administered ipilimumab survived longer without experiencing melanoma recurrence, with an average recurrence-free survival of 26.1 months in ipilimumab treated patients and 17.1 months in placebo treated patients.
  • Additionally, 46.5% ipilimumab treated patients survived 3 years without experiencing recurrence, while 34.8% placebo treated patients survived 3 years without recurrence.

CareAcross-vial-and-syringe

Researchers wanted to determine if ipilimumab could improve the survival of advanced-stage melanoma patients if it was given after the surgical removal of both their primary melanoma tumors and their regional lymph nodes and if particular patient characteristics were associated with a better response to therapy.

They discovered that patients who had microscopic metastatic disease in their regional lymph nodes and a tumor that had a breakdown of the overlaying skin responded best to ipilimumab treatment.

Promising results but with serious adverse events

Despite these promising results, ipilimumab treatment was associated with significantly higher toxicity than placebo treatment, including higher rates of gastrointestinal disorders, alterations in kidney function and inflammation of the pituitary gland. These adverse events resulted in 52% patients on ipilimumab discontinuing treatment before its completion, including 39% patients during the first four doses of ipilimumab. Furthermore, 5 patients on ipilimumab died during treatment due to adverse events.

The dose used in this study was significantly higher than the dose commonly used in melanoma patients. Additional studies are required to ensure that the benefit of this dose of ipilimumab does not outweigh the added toxicity risks.

Source: Science Daily
No Comment